[CAS NO. 1197824-15-9] EN4
PRODUCTS SPECIFICATIONS [1197824-15-9]
DESCRIPTION [1197824-15-9]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 416.47 |
| Molecular Formula | C25H24N2O4 |
| SMILES | O=C(NC1=CC=CC=C1OC2=CC=C(OCC)C=C2)C3=CC=C(CNC(C=C)=O)C=C3 |
Summary
In Vitro
EN4 (1-50 μM; for 72 hours) treatment significantly impaires 231MFP breast cancer cell proliferation in a dosedependent manner, with >90% inhibition of proliferation at 50 μM
[1]
.
EN4 (50 μM; for 60 hours) treatment significantly decreases the protein levels of representative MYC-regulated target genes, including CDK2 and CDC25A. EN4 treatment also substantially reduces MYC levels
[1]
.
EN4 shows the strongest inhibition of both MYC/MAX binding to its DNA consensus sequence in vitro as well as MYC transcriptional activity in cells. EN4 inhibited MYC/MAX binding to the E-box response element DNA consensus sequence in a dose-responsive manner with an IC50 value of 6.7 μM. EN4 also inhibits MYC luciferase reporter activity in a dose-responsive manner with an IC50 value of 2.8 μM
[1]
.
EN4 (50 μM; for 2 hours) treatment significantly reduced MYC thermal stability in 231MFP breast cancer cells
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay [1]
| Cell Line: | 231MFP breast cancer cells |
| Concentration: | 1 μM, 10 μM, 50 μM |
| Incubation Time: | 72 hours |
| Result: | Significantly impaired 231MFP breast cancer cell proliferation in a dose-dependent manner. |
Western Blot Analysis [1]
| Cell Line: | 231MFP breast cancer cells |
| Concentration: | 50 μM |
| Incubation Time: | 60 hours |
| Result: | The protein levels of CDK2 and CDC25A were significantly lowered. |
In Vivo
EN4 (50 mg/kg; intraperitoneal injection; daily; for 3 weeks) treatment significantly attenuated tumor growth in 231MFP breast tumor xenograft mice [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | SCID mice injected with 231MFP breast cancer cells [1] |
| Dosage: | 50 mg/kg |
| Administration: | Intraperitoneal injection; daily; for 3 weeks |
| Result: | Significantly attenuated tumor growth in vivo. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 125 mg/mL ( 300.14 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4011 mL | 12.0057 mL | 24.0113 mL |
| 5 mM | 0.4802 mL | 2.4011 mL | 4.8023 mL |
| 10 mM | 0.2401 mL | 1.2006 mL | 2.4011 mL |